B-Chronic Lymphocytic Leukemia Autophagyc Cell Death by the Use of Manganese Doped Zinc Oxide Nanoparticles and Photo-Dynamic Therapy

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloUniversidad Nacional de La Plataes
cic.versioninfo:eu-repo/semantics/publishedVersiones
dc.date.accessioned2021-10-28T15:47:53Z
dc.date.available2021-10-28T15:47:53Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/11349
dc.titleB-Chronic Lymphocytic Leukemia Autophagyc Cell Death by the Use of Manganese Doped Zinc Oxide Nanoparticles and Photo-Dynamic Therapyen
dc.typeArtículoes
dcterms.abstractB-Chronic Lymphocytic Leukemia (B-CLL) usually follows an adverse, relentless clinical course by slowly developing drug resistance to fludarabine and other chemotherapeutic agents, as well as by acquiring new different genetic abnormalities. As B-CLL cells spontaneously produce high amounts of Reactive Oxygen Species (ROS) having an altered redox state in relation to that of normal B lymphocytes, we decided to probe different metal Zinc nanoparticles (ZnNPs) and quantify the levels of Singlet Oxigen (SO) to see if variations of its intracellular concentrations could execute and accelerate deadly programs in leukemic cells rather than in normal B lymphocytes, when applied with Photodynamic Therapy (PDT). In this way, we developed and tested a variety of metal ZnNPs of which one made of 0.5% Manganese Doped Zinc Oxide (ZnO:Mn) was finally selected for further testing as it had the best fludarabine resistant B-CLL cells in vitro killing activity, specially when combined with PDT. An interesting and rapidly dying process of B-CLL cells, known as autophagy, was always seen under Transmission Electronic Microscopy (TEM) when incubated with these 0.5% Mn doped ZnO NPs. This phenomenon correlated well with those intracellular increases of SO when PDT was administered, and measured by a novel method first described by us. As this therapy seems to be very specific to fludarabine resistant B-CLL cells, producing almost no damage to normal lymphocytes, it could surely contribute in the near future as a new innovative targeted strategy to be delivered in the clinical setting for the definitive benefit of these bad prognostic patients.en
dcterms.creator.authorPeña Luengas, Sandraes
dcterms.creator.authorMarín, Gustavo H.es
dcterms.creator.authorRodriguez Nieto, Felipe Jorgees
dcterms.creator.authorDreon, Marcos Sebastiánes
dcterms.creator.authorRoque, Gustavoes
dcterms.creator.authorNúñez, Luises
dcterms.creator.authorSánchez, Fransiscoes
dcterms.creator.authorTarditti, Adriánes
dcterms.creator.authorSchinella, Guillermo Raúles
dcterms.creator.authorPistaccio, Luises
dcterms.creator.authorGoya, Rodolfoes
dcterms.creator.authorTau, Jose Mariaes
dcterms.creator.authorIchim, Thomases
dcterms.creator.authorRiordan, Neiles
dcterms.creator.authorRivera Montalvo, Luises
dcterms.creator.authorMansilla, Eduardoes
dcterms.extent15-25es
dcterms.identifier.otherISSN: 0975 4415es
dcterms.identifier.urlRecurso onlinees
dcterms.isPartOf.issuevol. 5, no. 1es
dcterms.isPartOf.seriesInternational Journal of Drug Delivery Technologyes
dcterms.issued2014
dcterms.languageIngléses
dcterms.licenseAttribution 4.0 International (BY 4.0)es
dcterms.subjectB-Chronic Lymphocytic Leukemiaen
dcterms.subjectMetal ZnNPsen
dcterms.subject.materiaCiencias Químicases
dcterms.subject.materiaCiencias Médicases

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
B-Chronic Lymphocytic Leukemia Autophagyc.pdf-PDFA.pdf
Tamaño:
949.76 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo